U.S. News Room
November 10, 2025
DS3610 Enters Clinical Development in Patients with Advanced Solid Tumors as First STING Agonist ADC in Industry-Leading ADC Portfolio of Daiichi Sankyo
Download
October 30, 2025
DESTINY-Lung06 Phase 3 Trial of ENHERTU Initiated as First-Line Therapy in Patients with HER2 Overexpressing Metastatic Non-Squamous Non-Small Cell Lung Cancer
Download
October 19, 2025
DATROWAY Demonstrated an Unprecedented Median Overall Survival Improvement of Five Months Versus Chemotherapy as First-line Treatment for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02 Phase 3 Trial
Download
October 19, 2025
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2,3 Trial
Download